Nordic Issuing

Ongoing case

Kancera AB

Back to all cases

Kancera AB

1 Nov - 15 Nov 2022Rights issue

Kancera is a world leader in developing small molecule drugs for cancer and inflammation.

The company’s two main drug candidates are KAND567 in phase II for treatment of acute inflammatory conditions, and KAND145 in clinical preparatory studies prior to the start of phase I for treatment-resistant ovarian cancer. Kancera is listed on Nasdaq OMX First North Premier since 2016. The company is based at Karolinska Institutet Science Park in Stockholm, a world-leading center for medical innovations. Kancera has mainly focused on cancer and inflammatory diseases. As research consultants, Kancera’s team has carried out projects for pharmaceutical companies and biotech companies in the USA as well as in Europe. Among these assignments is, for example, the development of the chemistry that laid the foundation for Enasidenib, a drug that has been marketed since 2017 by the American pharmaceutical company Bristol Myers Squibb for the treatment of acute leukemia (AML).

Read more on the company's website

The offer in summary

Record date: 28 October 2022

Subscription period: 1 November - 15 November 2022

Subscription rights: Shareholders by the record date of 28 October 2022 will obtain one (1) unit right per existing share. In order to subscribe for one (1) new unit, fifteen (15) unit rights are exercised. Every unit consist och twelve (12) new shares ande four (4) subscription warrants (TO 6).

Subscription price: SEK 24.00 per unit

Emission volume: Maximum of 3 742 929 units which corresponds to about MSEK 90

Trading with unit rights: 1 November - 10 November 2022

Marketplace: Nasdaq First North Growth Market

Financial advisor: Stockholm Corporate Finance


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.